HSBC Reiterates Buy Rating on Regeneron Pharmaceuticals, Inc. (REGN)

Market Context

Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $649.81 with a market capitalization of $77.2B. The stock has gained 0.9% over the past 52 weeks.

Analyst coverage from HSBC provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Regeneron Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Regeneron Pharmaceuticals, Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	Benchmark	Buy	N/A
Jul 06, 2026	HSBC	Buy	N/A
Jul 06, 2026	Cantor Fitzgerald	Overweight	N/A
May 19, 2026	Canaccord Genuity	Buy	N/A
May 18, 2026	BMO Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View REGN Stock Page